Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

MicroRNA Markers for Osteosarcoma Predictive Prognosis

Technology #20130130

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
MicroRNA Predictive MarkersCanine OsteosarcomaOsteosarcoma
Categories
Researchers
Subbaya Subramanian, PhD
Department of Surgery
External Link (www.surgery.umn.edu)
Dr. Subramanian’s Research
External Link (www.tc.umn.edu)
Jaime Modiano,VMD, PhD Professor, Veterinary Clinical Sciences
Dr. Modiano’s interests are the mechanisms of neoplastic transformation and tumor progression.
External Link (www.cvm.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

PCT Patent Application PCT/US2013/069237

MicroRNA with Prognostic and Predictive Markers of Osteosarcoma

MicroRNA based markers that may allow for the predicted prognosis in human and canine osteosarcoma have recently been discovered. This genetic signature microRNA panel provides prognostic and predictive markers that may aid in determining the aggressiveness, risk of metastasis, and poor outcomes in patients diagnosed with osteosarcoma. The genetic signature used in this technology is identical in humans and canines, allowing it to be used for either patient population. The advantages of this system are that it allows for easy clinical setup and has shown an improvement in prognosis accuracy. Knowing the likelihood of how aggressive the cancer is, or will get, allows for better selection of the right treatment.

MN-IP Try and Buy
Try
  • Trial period: 12 to 18 months. $5000/6 months.
  • Fee waived if MN-based company or if sponsoring $50,000+ in research.
Buy
  • Exclusive license for a $15,000 conversion payment.
  • Additional patent expenses due.
  • 3% royalty after $1 million of product sales.
  • Discount for MN companies.

** View the Term Sheet **
** Contact Rebecca Gerber for specific details. **

MicroRNA in the Prediction of Osteosarcoma Development and Metastatic Potential

Currently there are no microRNA based markers on the market that can predict prognosis or aggressiveness in human and canine osteosarcoma. Osteosarcoma is the most common form of primary bone tumor majorly affecting children and adolescents. Developing tumors in naturally occurring cancers are thought to be contributed by microRNA. Looking at microRNA expression may potentially be a predictor of the development of osteosarcoma and metastatic potential. Osteosarcoma is currently studied in canines due to the two year timeframe of diagnosis that allows for risk assessment, prediction, and outcome to be successfully carried out.

BENEFITS OF THE OSTEOSARCOMA DIAGNOSTIC:

  • Genetic signature microRNA panel with prognostic and predictive markers that allow determination of aggressiveness of cancer, better predicted risk of metastasis, and identification of possible outcomes
  • Same genetic signature found in humans and canines- can be used in either patient population and allows for better selection of treatment
  • Accuracy and easy use in clinical setup
  • New breakthrough in human and canine osteosarcoma diagnostics